1 Automatic Retinoblastoma Screening and Surveillance

2

Using Deep Learning

- 3 Ruiheng Zhang, MD^{1, #}, Li Dong, MD^{1, #}, Ruyue Li, MSc^{2, #}, Kai Zhang, PhD^{3 #},
- 4 Yitong Li, MSc^{1, #}, Hongshu Zhao, MD⁴, Jitong Shi, MD⁴, Xin Ge, MD⁴, Xiaolin
- 5 Xu, MD⁴, Libin Jiang, MD⁴, Xuhan Shi, MD¹, Chuan Zhang, MD¹, Wenda Zhou,
- 6 MSc¹, Liangyuan Xu, MSc⁴, Haotian Wu, MSc¹, Heyan Li, MSc¹, Chuyao Yu, MSc
- ¹, Jing Li⁴, Jianmin Ma, MD^{4,*}, Wenbin Wei, MD^{1,*}
- ¹Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor
- 9 Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab,
- 10 Medical Artificial Intelligence Research and Verification Key Laboratory of the
- 11 Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital
- 12 Medical University, Beijing, China.
- ²Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren
- 14 Hospital, Capital Medical University, Beijing, China.
- ³ InferVision Healthcare Science and Technology Limited Company, Shanghai,
- 16 China.
- ⁴ Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Eye
- 18 Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- [#] These authors contributed equally to the study.^{*} Correspondence author: Jianmin Ma
- 20 (<u>imma@sina.com</u>), Wenbin Wei (weiwenbintr@163.com).
- 21 Keywords: Retinoblastoma, Deep learning, Screening, Surveillance
- 22

23 ABSTRACT

24 Retinoblastoma is the most common intraocular malignancy in childhood. With the 25 advanced management strategy, the global salvage and overall survival have 26 significantly improved, which proposes subsequent challenges regarding long-term 27 surveillance and offspring screening. Here, we developed deep learning algorithm, 28 called Deep Learning Assistant for Retinoblastoma (DLA-RB) training on A total of 29 36623 images from 713 patients. We validated it in the prospectively collected dataset, 30 comprised of 1366 images form 139 eyes of 103 patients. In identifying active 31 retinoblastoma tumors (treatment required) from all clinical-suspected patients, the 32 area under the receiver operating characteristic curve (AUC) of DLA-RB reached 33 0.991 (95% CI 0.970-1.000). In identifying active retinoblastoma from stable 34 retinoblastoma patients (treatment is not required), AUC of DLA-RB reached 0.962 35 (95% CI 0.915-1.000), respectively. Cost-utility analysis revealed that DLA-RB based 36 diagnosis mode is more cost-effective in both retinoblastoma diagnosis and 37 retinoblastoma activity surveillance. The DLA-RB achieved high accuracy and 38 sensitivity in identifying active retinoblastoma from the normal and stable 39 retinoblastoma fundus. It can be incorporated within telemedicine programs in the 40 future.

41 Introduction

42 Retinoblastoma is the most common intraocular malignancy in childhood. It is estimated to affect one case per 16,000-18,000 live births worldwide.¹ China, India, 43 44 and other populous countries in Asia and Africa have the largest amount of newly 45 diagnosed retinoblastoma patients. With advanced screening techniques and 46 multidisciplinary management, most retinoblastoma patients achieve life-saving, globe salvage, and even useful vision.² In a recent national cohort study in China, the 47 48 overall survival rates of RB patients were 81%, 83%, and 91% in patients diagnosed in 1989-2008, 2009-2013, 2014-2017, respectively.³ For globe salvage, almost all 49 50 retinoblastoma classified by the International Intraocular Retinoblastoma 51 Classification (IIRC)⁴ as group A-C can achieve globe salvage through systemic chemotherapy with adjuvant laser therapy and cryotherapy.⁵ Group D retinoblastoma 52 53 can also achieve 40% (95%CI:31–51%) globe salvage rate through chemotherapy alone ⁶ and a significantly higher globe salvage rate when receiving intra-ophthalmic 54 55 artery chemotherapy.⁷

Improved overall survival and successful local control propose subsequent challenges
regarding long-term surveillance after tumor control and screening for the offspring
and relatives of retinoblastoma survivors. The current expert consensus recommends
every 2–6 months for 4 years after tumor control.¹ In real-world practice, group D
retinoblastoma received an average of 21 examinations under anesthesia (EUAs)
during 5-year follow-up.⁸ Furthermore, offspring of retinoblastoma survivors have 50%

62 chance of inheriting the mutant RB1 from the affected parent, which would result in a 63 97% risk of developing retinoblastoma.⁹ Global preserving approach thus leads to 64 additional disease burden comprised of health care, socioeconomic, and mental 65 aspects. Furthermore, in most developing countries, only experienced medical 66 ophthalmologists at tertiary eye centers can perform EUAs. This unbalanced 67 distribution of health care resources may delay the diagnosis and proper management 68 during the referring process.

69 The application of deep learning (DL) techniques proposes reliable and low-cost 70 methods for screening and diagnosing retinal diseases. Previous studies showed that 71 the DL algorithm based on fundus images achieves close-to-expert performance for the automatic detection of retinal diseases, including diabetic retinopathy¹⁰. 72 age-related macular degeneration (AMD),¹¹ glaucoma,¹² myopic maculopathy,¹³ rand 73 74 papilledema.¹⁴ Recently, researchers have applied DL in detecting plus diseases in retinopathy of prematurity.^{15,16} The DL algorithm exceeds 6 of 8 experts in identifying 75 76 plus diseases, which indicates it can reach robust performance in images obtained by 77 EUAs.

78 Thus, in the current study, we developed Deep Learning Assistant for Retinoblastoma 79 (DLA-RB) and validated it in the prospectively collected dataset. The DLA-RB aims 80 to assist the fundus surveillance after local control and provide referral advice. The 81 DLA-RB also provides automatic surveillance of the contralateral eye of 82 retinoblastoma patients and the offspring of retinoblastoma survivors.

83

84 **Results**

85 Between March 2018 and January 2022, 47503 images from 713 patients were 86 retrospectively collected from the anonymous data center in Beijing Tongren hospital 87 (Figure 1). After manually excluding low-quality images due to non-fundus image, 88 halation, blurs, and defocus (Supplementary Figure S1), a total of 36623 images 89 from 713 patients were finally included for DLA-RB development, with 19045 90 (52.0%), 2918 (8.0%), and 14660 (40.0%) images were normal, stable and active 91 retinoblastoma (Supplementary Table S1). At patient levels, 713 patients were 92 randomly allocated for DLA-RB development and five-fold cross-validation. 93 Considering that it is more complicated to distinguish between stable and active 94 retinoblastoma, we first trained ResNet-50 and InceptionResnetV3 for this two-class 95 task to compare the performance of these two architectures. ROC indicated slight 96 better performance of ResNet-50 in five-fold cross-validation (0.940 [95%CI 97 0.851-0.996] vs. 0.934 [95%CI 0.735-0.946], Supplementary Figure S2). Thus, 98 ResNet-50 was used to establish DLA-RB. To distinguish between the normal fundus 99 and active lesion, DLA-RB achieved an AUC of 0.9982 (95%CI 0.986-1.000) in the 100 development dataset (Supplementary Figure S3).

101 From February 2022 to June 2022, 103 patients with clinical-suspected
102 retinoblastoma and treated retinoblastoma patients first visited Beijing Tongren
103 hospitals. Fundus images of these patients were not used in developing DLA-RB. If

104	more than one time of EUA, only the first EUA images were collected. In total, 139
105	eyes of 103 patients were included for prospective validation (Table 1). 69 eyes were
106	clinically diagnosed with retinoblastoma. According to international intraocular
107	retinoblastoma classification (IIRC), ¹⁷ 3 (4.3%), 7 (10.1%), 8 (11.6%), 40 (58.0%),
108	and 11 (15.9%) eye was classified as A-E stage, respectively. 43.5% of
109	retinoblastoma was endophytic, while 56.5% were exophytic. For each EUA, the
110	highest probability among all images was assigned as an eye-level probability.
111	DLA-RB could accurately identify active retinoblastoma tumors from all
112	clinical-suspected retinoblastoma (Figure 2A-B, Table 2). The AUC, sensitivity, and
113	specificity reached 0.991 (95%CI 0.970-1.000), 0.979 (95%CI 0.927-1.000), and
114	1.000 (95%CI 1.000-1.000), respectively. Compared with the human
115	ophthalmologists, the DLA-RB reached significantly higher sensitivity and specificity
116	in identifying new retinoblastoma tumors (Figure 2A-B, Supplementary Table
117	S2-3). The only misclassified case of DLA-RB was a Group A retinoblastoma located
118	at superior-nasal ora Serrata (Supplementary Figure S1).
119	DLA-RB could also accurately distinguish active retinoblastoma from stable
120	retinoblastoma (Figure 2C-D Table 2) Among all referred and treated

retinoblastoma (**Figure 2C-D, Table 2**). Among all referred and treated retinoblastoma patients, the AUC, sensitivity, and specificity reached 0.962 (95%CI 0.915-1.000), 0.978 (95%CI 0.932-1.000), and 0.800 (95%CI 0.556-1.000) respectively. Compared with competent ophthalmologists, the DLA-RB reached superior sensitivity yet inferior specificity in identifying active retinoblastoma from

125	stable retinoblastoma (Figure 2C-D, Supplementary Table S2-3). Of all 4
126	misclassified cases in this task, 3 cases were false-positive, whereas only 1 case was
127	false-negative (Table 4).

Heatmap visualization revealed that the DLA-RB mainly focused on the tumor of the
newly-diagnosed retinoblastoma (Figure 3A). The DLA-RB focused on the relapse
site of retinoblastoma on fundus images (Figure 3B).

131 DLA-DR has proven to be sensitive and accuracy in identifying active retinoblastoma 132 from the normal fundus and stable retinoblastoma fundus. Yet, the cost-effectiveness 133 of a DLA-RB based approach to screen and surveillance retinoblastoma is unknown. 134 **Table 4** shows the base-case results of the cost-utility analysis. For identifying active 135 retinoblastoma tumors from all clinical-suspected retinoblastoma, the cumulative 136 costs for traditional ophthalmologic centers-based diagnosis mode and DLA-RB 137 based diagnosis mode were \$4882 and \$3519, respectively, and cumulative 138 quality-adjusted life-year (QALYs) for both diagnosis modes were 2.87769 and 139 2.8724 respectively. Compared with DLA-RB based diagnosis mode, the traditional 140 ophthalmologic centers-based diagnosis mode was not cost-effective since it resulted 141 in a gain of 1 QALY at the cost of \$257645. For distinguishing active retinoblastoma 142 from stable retinoblastoma patients, the cumulative costs and QALYs for traditional 143 ophthalmologic centers-based diagnosis mode were \$7614 and 5.46436, and the 144 figures for DLA-RB-based diagnosis mode were \$6981 and 5.46345. Traditional 145 ophthalmologic centers-based diagnosis mode was still unsatisfied with the

146 cost-effectiveness threshold since it produced an ICUR of \$694323. Therefore,
147 DLA-RB based diagnosis mode is cost-effective option in both RB diagnosis and
148 active lesion identification progress.

149 The tornado diagram shows the parameters that had the greatest impacts on base-case

150 outcomes and how much they influenced the outcomes (**Supplementary Figure S5**).

151 Probabilistic sensitivity analyses were conducted by taking 10000 random draws

152 surrounding the basic values (Supplementary Figure S6). According to

153 cost-effectiveness acceptability curves, at the current cost-effectiveness threshold,

DLA-RB based diagnosis mode had a 100% probability of being the more
cost-effective option in the process of RB diagnosis from all clinical-suspected
retinoblastoma, and it had a 59% probability to be cost-effective for identification of

157 active retinoblastoma from all treated retinoblastoma patients.

158

159 **Discussion**

In the current study, we developed Deep Learning Assistant for Retinoblastoma (DLA-RB) that could accurately identify active retinoblastoma from the normal fundus and stable retinoblastoma fundus. The DLA-RB further exhibited superior sensitivity in identifying newly onset retinoblastoma and similar sensitivity in identifying relapse retinoblastoma. The diagnosis accuracy and sensitivity were superior/non-inferior than competent with about 2-5 years of experience in EUAs

166 examination. Compared with referral procedures to ophthalmologic centers, DLR-RB

167	based approach is	cost-effective and read	lilv implei	mented in the re	gional hospital.
					0

168 According to the consensus from the American Association of Ophthalmic 169 Oncologists and Pathologists, children with a family history of the retinoblastoma are highly recommended to take sufficient retina examination until the age of 7.¹⁸ Among 170 171 all family members of retinoblastoma patients, offspring of bilateral have near 50% 172 risk. In contrast, other siblings and nieces/nephews have less than 2.5% risk of 173 harboring RB1 mutation. EUA is strongly recommended for any child unable to 174 participate in an office examination sufficiently to allow a thorough examination of the retina.¹⁸ However, the frequent screening schedule is often limited by the scarcity 175 of ophthalmological resources, especially in underdeveloped regions.¹⁹ Here, we 176 177 proposed a novel screening solution for offspring and family members of patients. 178 DLA-RB showed high efficiency with 0.991 of AUC and 0.979 sensitivity in the 179 prospective validation dataset. The diagnostic accuracy and sensitivity of DLA-RB 180 surpassed competent ophthalmologists. In real-world practice, the DLA-RB could 181 provide automatic and real-time feedback on retinoblastoma screening, especially 182 among the high-risk population.

183 Nowadays, although advanced multidisciplinary management concepts have been 184 adopted in developed countries, less significant improvement in globe salvage rate 185 was seen in the lower-middle-income country.²⁰ DLA-RB could also be used as a 186 screening technique for the contralateral eye of unilateral retinoblastoma patients who

187	received primary enucleation. In a retrospective analysis comprising
188	unilateral-presenting Group D retinoblastoma patients, during a median time of
189	approximately 5 years follow-up, only 1 out of 55 developed a new tumor in the
190	contralateral eye. ⁸ Using DLA-RB at the local hospital could save time and financial
191	burden when ophthalmologic centers are not near at hand.

192 Through multidisciplinary management, the globe salvage rate in the high-income country has tremendously improved from 34% in 1980-89 to 70% in 2010-20.20 193 194 Based on a meta-analysis, retinoblastoma recurrence occurs in about 15% of patients.⁷ 195 Advanced retinoblastoma (IIRC Group D-E) has a significantly higher risk of 196 recurrence.²¹ Extensive recurrence of subretinal or vitreous seeds was the most 197 common cause of treatment failure and final enucleation. Thus, there are increasing 198 burden of tumor surveillance after intraocular local control. Here, DLA-RB showed 199 high sensitivity to detect active retinoblastoma in the background of stable 200 retinoblastoma appearance (calcification, atrophy, laser and cryotherapy scar, and 201 fibrosis). In real-world practice, DLA-RB can provide automatic assistance in 202 treatment decision-making.

In the past two decades, telemedicine technology has enabled the centralization of care at a single center in developing countries to achieve patient outcomes comparable to those of developed countries.²² Within the domain of telemedicine, the DLA-RB can largely contribute to lowering the burden in diagnosis and follow-up and concentrate the limited healthcare resource in making multidisciplinary management.

208 DLA-RB can also help to promote the availability of retinoblastoma screening and 209 surveillance by improving the early diagnosis of population at-risk and long-term 210 follow-up for retinoblastoma patients. Such an approach has successfully managed retinopathy of prematurity, a leading cause of childhood blindness worldwide. ^{15,16,23} 211 212 Despite these remarkable results, some inherent limitations of DLA-RB are worth 213 highlighting. First, the development and prospective validation of DLA-RB were 214 conducted in a single institution (Beijing Tongren Hospital). The generalizability of 215 diagnostic performance needs further validation. Yet, in the current study, fundus 216 images in the present study were captured by five ophthalmological experts and two 217 different commercially available cameras, which fully reflected the variability in 218 experience, image quality, resolution, different camera systems, operators' 219 illumination, and field of view. Thus, the result from the perspective validation 220 dataset can represent the performance of DLA-RB in real-world practice. Secondly, 221 retinoblastoma begins as a round, translucent, gray to white tumor in the retina, 222 similar to the halation caused by microbubble in couplant. Careful image quality 223 control was required for ophthalmologists. An artificial intelligence-based quality 224 control module is needed to incorporate with DLA-RB, which warrants further 225 development. Third, accurately identifying active retinoblastoma also rely on a 226 thorough examination of the posterior pole and peripheral retina, which depends on 227 the experience of the operator. A deep-learning-based operation indicator may need to 228 cooperate with DLA-RB to lower the risk of false-negative chance. Fourth, because of

229	the low incidence of retinoblastoma, only 103 patients were included in prospective
230	validation, which limited subgroup analysis. It warrants further study to explore the
231	diagnosis accuracy of DLA-RB in different IIRC group retinoblastoma.
232	In conclusion, DLA-RB achieved high accuracy and sensitivity in identifying active
233	retinoblastoma from the normal fundus and stable retinoblastoma fundus. Compared
234	with referral procedures to ophthalmologic centers, DLA-RB based automatic
235	screening and activity surveillance is also cost-effective. In the future, DLA-RB can
236	incorporate telemedicine programs to reduce the burden in diagnosis and follow-up
237	and concentrate the limited health-care resource in making multidisciplinary
238	management.

239

240 Methods

241 Clinical trial registration and ethics approval

242 This single-center diagnostic study was done in Beijing Tongren hospitals in China. 243 The methods were performed in accordance with relevant guidelines and regulations 244 and approved by the Medical Ethics Committee of Beijing Tongren Hospital. Because 245 individually identifiable information was removed during retrospective collection, 246 written informed consent was exempted in the retrospective collected dataset. In the 247 prospectively collected validation dataset, written informed consent was obtained 248 from all caregivers prior to their inclusion. This study was registered on 249 ClinicalTrials.gov (NCT05308043) on February 2022. Because this study was a

250 diagnostic study that did not assign designative interventions to participants, clinical

trial protocol is not applicable.

252 Dataset collection

253 Training and internal test dataset were retrospectively collected between March 2018 254 and January 2022. All EUAs were performed for screening or pretreatment 255 examination in daily clinical practice. Five ophthalmological experts (HS Zhao, X Ge, 256 XL Xu, LB Jiang, JS, and JM Ma) obtained images using a commercially available 257 camera (RetCam3; Natus Medical Incorporated) and the standard imaging protocol. In 258 brief, posterior pole and 12 clocks of peripheral retina images were obtained during 259 EUAs. Repeatedly images were taken if necessary. We collected all EUAs images 260 from patients clinically diagnosed with retinoblastoma. For patients with several 261 EUAs, we included all images in the retrospective dataset. Patients who were 262 considered with Coats' disease, persistent fetal vasculature and other retinal diseases 263 were excluded.

The validation dataset was prospectively collected from February 2022 to June 2022. Clinically suspected retinoblastoma and treated retinoblastoma patients that first visited Beijing Tongren hospitals were standard EUAs. Patients involved in algorithm development and considered to have other retinal diseases were excluded. During prospective collection, a new generation of a commercially available camera (RetCam3) was deployed in Beijing Tongren hospital with updated illumination and

270 imaging capture system. Thus, the prospective validation dataset was further divided

into two subsets (Equipment 1 and 2) to examine the reliability of new equipment.

272 Image quality control and labeling

273 All EUAs images were stored in jpeg format in the imaging databases. Poor-quality 274 images resulting from halation, blur, and defocus, as well as non-EUAs images, were 275 excluded manually. In addition, blurred images due to leukoplakia and secondary 276 cataract in advanced retinoblastoma were also excluded. A multidisciplinary 277 management team consisting of ophthalmology, pediatric and radiologist experts 278 made personal treatment strategies after EUAs. The personal treatment strategies 279 comprised a combination of a systemic chemotherapy regimen of carboplatin, 280 vincristine, etoposide, and focal consolidation therapy. Each chemotherapy cycle was 281 repeated every 3 to 4 weeks for 6 to 8 cycles, according to condition and tumor status. 282 Follow-up by EUAs was undertaken before each cycle of chemotherapy and every 3 283 to 4 weeks thereafter, during which the adjuvant laser therapy and cryotherapy were 284 applied as needed. In accordance with treatment strategies, five ophthalmological 285 experts (HS Zhao, X Ge, XL Xu, LB Jiang, JS, and JM Ma) with a minimum of 15 286 years of experience labeled all images as "normal fundus", "stable retinoblastoma" 287 that specific treatment is not required, and "active retinoblastoma" that specific 288 treatment is required.

289 Development of DLA-RB

290 The patients from the retrospective dataset were randomly split into training and the 291 internal validation dataset as five-fold cross-validation for developing and evaluating 292 the performance of DLA-RB, respectively. To automatically distinguish "normal 293 fundus", "stable retinoblastoma", and "active retinoblastoma", we first compared the performance of some architectures including ResNet-50 and InceptionV3.24-26 294 295 ResNet-50 which did not occupy much computational resource achieved better 296 performance and was chosen to complete the task. The input of the model was an 297 image from EUAs. The output of the first model is a binary output determined 298 whether the input image contained active retinoblastoma was among normal fundus 299 and active retinoblastoma. The second binary classification task for determining 300 among stable retinoblastoma and active retinoblastoma, whether the input image 301 contained active retinoblastoma. In addition, the training dataset is imbalanced, so we 302 adopted a class weight policy in the training process. All models were developed with 303 Tensorflow 1.10.0 and Keras 2.2.4 on the server with three NVIDIA 1080 GPUs (Graphical Processing Units).²⁷ All images were resized to 256×256 and then fed into 304 305 models to train or test. The optimization algorithm was SGD (Stochastic Gradient Descent)²⁸, the default hyperparameters in Keras 2.2.4 were used, and at the same 306 307 time, the batch size was 32. Besides, class weight was used for trading off the effect 308 of the imbalanced distribution of two classes. Based on the repeated experiments, 309 different epochs were also applied to train the models without underfitting. Moreover, 310 the best models in terms of validation accuracy is saved as the final deployed model.

311 Validation of DLA-RB

312	We first validated the performance of DLA-RB in identifying retinoblastoma activity
313	in patients using an internal validation dataset and a prospective validation dataset
314	from Beijing Tongren Hospital. For further performance evaluation, two varying
315	degrees of expertise (competent and trainee), masked to the patients' demographics
316	and final multidisciplinary management strategy, were asked to classify every patient
317	in the prospective dataset independently, and their results were compared with those
318	of DLA-RB. The competent ophthalmologists attended doctors with about 2-5 years
319	of experience in general ophthalmology and EUAs examination. The trainee was a
320	resident who had finished EUAs training.

321 Cost-utility analysis

322 Two Markov models were built using TreeAge Pro (TreeAge Software; Williamstown, 323 MA, USA) to compare the cost-effectiveness between traditional ophthalmologic 324 centers-based diagnosis mode and DLA-RB based diagnosis mode from a societal 325 perspective. For the first binary model, we simulated a hypothetical cohort of a 326 newborn with RB through 5 1-year Markov cycles. With the growth of age, children 327 could be found to have eye symptoms by their parents according to specific 328 probabilities and then go to the hospital. Diagnosed patients received routine 329 treatment and management, whereas undiagnosed patients could still be examined in 330 the next cycle. According to the Management Guidelines for Childhood Screening for 331 Retinoblastoma Families, we determined the screening intervals for undiagnosed patients.¹⁸ For the second binary model, simulated a hypothetical cohort of 332 333 2-year-old RB patients who have received regular treatment and were in an inactive

334 stage through a total of 3 1-year Markov cycles. They were routinely reviewed every

three months, and those who had active lesions received further treatment.

336 Parameters used in Markov models were collected from our study and previous 337 studies. Examination and treatment costs were collected in Chinese yuan from Beijing 338 Tongren Hospital and converted to US dollars at an exchange rate of 6.45 yuan per 339 dollar (Supplementary Table S4). Both direct and indirect costs were included, and 340 the specific composition of costs and annual costs of traditional ophthalmologic 341 centers-based diagnosis mode and DLA-RB-based diagnosis mode was shown in 342 Supplementary Table S5-6. Under traditional ophthalmologic centers-based 343 diagnosis mode, the patient and one accompanying family member spent more time in 344 tertiary hospitals or eye hospitals, resulting in transportation, accommodation, and 345 food costs. In DLA-RB-based diagnosis mode, we charged an additional \$15.5 for 346 each use. Only one accompanying family member's wage loss was counted.

347 Primary results were incremental cost-utility ratios (ICURs), which were calculated348 using the following formula:

349 *ICURs* = incremental cost/quality adjusted life years gained.

China's per capita gross domestic product (GDP) in 2021 was \$12551. According to the WHO definition, intervention costing between 1 to 3 times the per capita GDP was cost-effective, costing less than the per capita GDP was highly cost-effective, and costing more than three times the per capita GDP was not cost-effective. ²⁴ Both 1-way deterministic and simulated probabilistic sensitivity analyses were performed to test the sensitivity and robustness of base-case values, the uncertainty ranges of parameters were presented in **Supplementary Table S7**.

357 Visualization and statistical analysis

358	To visualize the decision ways of the model used, we applied the Grad-CAM to
359	generate heatmaps. ²⁵ The performance of DLA-RB was estimated by accuracy,
360	sensitivity, specificity, positive predictive value, negative predictive value, and F1
361	score for the identification of each category. We used the receiver operating
362	characteristic (ROC) curve and precision-recall curve to show the diagnostic
363	performance of the DLA-RB in discriminating binary classification tasks. N-out-of-N
364	Bootstrapping with 1000 replicates was used to estimate 95% confidence intervals (95%
365	CI) of the performance metrics at eye level. Human ophthalmologists' performance
366	was compared with 95% CI of DLA-RB.
367	All statistical analysis was performed using R Statistical Software (version 4.1.1; R
368	Foundation for Statistical Computing, Vienna, Austria), Stata (17.0, StataCorp LLC,
369	College Station, TX).
370	Data availability
371	Python scripts enabling the main steps of the analysis are available from the
372	corresponding author on reasonable request. The data and materials in this study are
373	available from the corresponding author on reasonable request.
374	Role of the funding source
375	The funders had no role in the study design, data collection, data analysis, data
376	interpretation, or in the writing of the manuscript.
377	

378	Acknowledgments:	The authors thanks	Beijing Hos	pitals Authority	' Ascent Plan

- 379 (DFL20190201); National Natural Science Foundation of China (82141128); The
- 380 Capital Health Research and Development of Special (2020-1-2052);
- 381 Science & Technology Project of Beijing Municipal Science & Technology Commissi
- 382 on (Z201100005520045, Z181100001818003) for supporting this study.
- 383 Contributors: JMM, RHZ and DL contributed to the concept of the study. JMM,
- 384 WBW critically reviewed the manuscript. RHZ, LD, RYL, KZ, and YTL designed the
- 385 study and did the literature search. RHZ, LD, RYL, KZ, YTL, HSZ, JTS, XG, XLX,
- 386 LBJ, XHS, CZ, WDZ, LYX, HTW, HYL, CYY, and JL collected the data. RHZ, LD,
- 387 RYL,KZ, and YTL contributed to the design of the statistical analysis plan. RHZ, LD,
- and KZ did the data analysis and data interpretation. RHZ and RYL drafted the
- 389 manuscript. JMM and WBW provided research funding, coordinated the research, and
- 390 oversaw the project. All authors had access to all the raw datasets and the
- 391 corresponding authors (JMM and WBW) has verified the data and had final decision
- to submit for publication. All authors reviewed and approved the final manuscript
- 393 **Competing Interests**: All authors declare that the research was conducted in the 394 absence of any commercial or financial relationships that could be construed as a 395 potential conflict of interest.

396 **References**

- 397 1 Dimaras, H. *et al.* Retinoblastoma. *Nat Rev Dis Primers* 1, 15021,
 398 doi:10.1038/nrdp.2015.21 (2015).
- 399 2 Fabian, I. D. *et al.* The management of retinoblastoma. *Oncogene* 37, 1551-1560,
- 400 doi:10.1038/s41388-017-0050-x (2018).
- 401 3 Luo, Y. et al. Contemporary Update of Retinoblastoma in China: Three-Decade
- 402 Changes in Epidemiology, Clinical Features, Treatments, and Outcomes. Am J

403 *Ophthalmol* **236**, 193-203, doi:10.1016/j.ajo.2021.09.026 (2022).

404 4 Linn Murphree, A. Intraocular retinoblastoma: the case for a new group classification.

405 *Ophthalmol Clin North Am* **18**, 41-53, viii, doi:10.1016/j.ohc.2004.11.003 (2005).

- 406 5 Stathopoulos, C. *et al.* Current Indications of Secondary Enucleation in
- 407 Retinoblastoma Management: A Position Paper on Behalf of the European
- 408 Retinoblastoma Group (EURbG). *Cancers (Basel)* **13**, doi:10.3390/cancers13143392
- 409 (2021).
- 410 6 Daniels, A. B. *et al.* Effect of Intravenous Chemotherapy Regimen on Globe Salvage
- 411 Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis.
 412 *Cancers (Basel)* 13, doi:10.3390/cancers13092216 (2021).
- 413 7 Chen, Q. *et al.* Comparison between intravenous chemotherapy and intra-arterial
- 414 chemotherapy for retinoblastoma: a meta-analysis. *BMC Cancer* 18, 486,
- 415 doi:10.1186/s12885-018-4406-6 (2018).
- 416 8 Fabian, I. D. et al. Primary enucleation for group D retinoblastoma in the era of

- 417 systemic and targeted chemotherapy: the price of retaining an eye. Br J Ophthalmol
- 418 102, 265-271, doi:10.1136/bjophthalmol-2017-310624 (2018).
- 419 9 Dimaras, H. *et al.* Retinoblastoma. *Lancet* **379**, 1436-1446,
- 420 doi:10.1016/S0140-6736(11)61137-9 (2012).
- 421 10 Gulshan, V. et al. Development and Validation of a Deep Learning Algorithm for
- 422 Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA 316,
- 423 2402-2410, doi:10.1001/jama.2016.17216 (2016).
- 424 11 Peng, Y. *et al.* DeepSeeNet: A Deep Learning Model for Automated Classification of
- 425 Patient-based Age-related Macular Degeneration Severity from Color Fundus

426 Photographs. *Ophthalmology* **126**, 565-575, doi:10.1016/j.ophtha.2018.11.015 (2019).

427 12 Li, Z. et al. Efficacy of a Deep Learning System for Detecting Glaucomatous Optic

428 Neuropathy Based on Color Fundus Photographs. *Ophthalmology* **125**, 1199-1206,

- 429 doi:10.1016/j.ophtha.2018.01.023 (2018).
- 430 13 Tan, T. E. *et al.* Retinal photograph-based deep learning algorithms for myopia and a
- 431 blockchain platform to facilitate artificial intelligence medical research: a retrospective
- 432 multicohort study. *The Lancet. Digital health* 3, e317-e329,
 433 doi:10.1016/S2589-7500(21)00055-8 (2021).
- 434 14 Milea, D. *et al.* Artificial Intelligence to Detect Papilledema from Ocular Fundus
- 435 Photographs. *N Engl J Med* **382**, 1687-1695, doi:10.1056/NEJMoa1917130 (2020).
- 436 15 Brown, J. M. *et al.* Automated Diagnosis of Plus Disease in Retinopathy of Prematurity
- 437 Using Deep Convolutional Neural Networks. JAMA Ophthalmol 136, 803-810,

- 438 doi:10.1001/jamaophthalmol.2018.1934 (2018).
- 439 16 Redd, T. K. et al. Evaluation of a deep learning image assessment system for 440 detecting severe retinopathy of prematurity. Br J Ophthalmol. 441 doi:10.1136/bjophthalmol-2018-313156 (2018). 442 17 Shields, C. L. et al. The International Classification of Retinoblastoma predicts 443 chemoreduction 113, 2276-2280, success. **Ophthalmology** 444 doi:10.1016/j.ophtha.2006.06.018 (2006). 445 18 Skalet, A. H. et al. Screening Children at Risk for Retinoblastoma: Consensus Report 446 from the American Association of Ophthalmic Oncologists and Pathologists. 447 *Ophthalmology* **125**, 453-458, doi:10.1016/j.ophtha.2017.09.001 (2018). 448 19 Ramirez-Ortiz, M. A. et al. Diagnostic delay and sociodemographic predictors of stage 449 at diagnosis and mortality in unilateral and bilateral retinoblastoma. Cancer Epidemiol 450 Biomarkers Prev23, 784-792, doi:10.1158/1055-9965.EPI-13-1069 (2014). 451 20 Wong, E. S. et al. Global retinoblastoma survival and globe preservation: a systematic 452 review and meta-analysis of associations with socioeconomic and health-care factors. 453 Lancet Glob Health 10, e380-e389, doi:10.1016/S2214-109X(21)00555-6 (2022). 454 21 Munier, F. L. et al. Conservative management of retinoblastoma: Challenging 455 orthodoxy without compromising the state of metastatic grace. "Alive, with good vision 456 and no comorbidity". Progress in retinal and eye research 73, 100764, 457 doi:10.1016/j.preteyeres.2019.05.005 (2019).
- 458 22 Yousef, Y. A. *et al.* How Telemedicine and Centralized Care Changed the Natural

459		History of Retinoblastoma in a Developing Country: Analysis of 478 Patients.
460		<i>Ophthalmology</i> 128 , 130-137, doi:10.1016/j.ophtha.2020.07.026 (2021).
461	23	Morrison, S. L., Dukhovny, D., Chan, R. V. P., Chiang, M. F. & Campbell, J. P.
462		Cost-effectiveness of Artificial Intelligence-Based Retinopathy of Prematurity
463		Screening. JAMA Ophthalmol 140, 401-409, doi:10.1001/jamaophthalmol.2022.0223
464		(2022).
465	24	Hutubessy, R., Chisholm, D. & Edejer, T. TT. Generalized cost-effectiveness
466		analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1,
467		8 (2003).
468	25	Selvaraju, R. R. et al. in Proceedings of the IEEE international conference on
469		computer vision. 618-626.
470		

472 Figure legends

- 473 **Figure 1**. Workflow diagram for the development and evaluation of DLA-RB.
- 474 RB, retinoblastoma.
- 475 **Figure 2**. Receiver operating characteristic curves and precision-recall curve of
- 476 DLA-RB performance in prospective validation dataset.
- 477 Receiver operating characteristic and precision-recall curve of DLA-RB in identifying
- 478 normal-active lesion identification (A-B), and stable-active lesion identification
- 479 (C-D).
- 480 Figure 3. Heatmap Visualization of DLA-RB
- 481 Heatmap demonstrating representative lesions, shown in original fundus image (first
- 482 column), general heatmap (second column) for (A) identifying active retinoblastoma
- 483 tumors from all clinical-suspected retinoblastoma and (B) identifying active
- 484 retinoblastoma from all referred and treated retinoblastoma patients.

	Equipment 1	Equipment 2	
Number of patients	64	39	
Age at diagnosis			
<12month	14 (21.9%)	11 (28.2%)	
12-23 month	19 (29.7%)	15 (38.5%)	
24-35 month	14 (21.9%)	6 (15,4%)	
≥36 month	17 (26.6%)	7 (17.9%)	
Gender			
male	36 (56.3%)	23 (59.0%)	
female	28 (43.8%)	16 (41.0%)	
Laterality			
unilateral	44 (68.7%)	22 (56.4%)	
bilateral	19 (29.7%)	16 (41.0%)	
Number of eyes	88	51	
IIRC Grade			
normal fundus	46 (52.3%)	24 (47.1%)	
A	3 (3.4%)	0 (0.0%)	
В	5 (5.7%)	2 (3.9%)	
C	6 (6.8%)	2 (3.9%)	
D	22 (25.0%)	18 (35.3%)	
E	6 (6.8%)	5 (9.8%)	
Number of eyes with retinoblastoma	42	27	
Tumor focality			
unifocal	16 (38.1%)	4 (14.8%)	
multifocal	26 (61.9%)	23 (85.2%)	
Retinoblastoma growth pattern			
endophytic	24 (57.1%)	15 (55.6%)	

486 Table 1. Basic characteristics of patients in prospective validation dataset.

exophytic	18 (42.9%)	12 (44.4%)
Fovea involvement		
not involved	14 (33.3%)	6 (22.2%)
subfoveal fluid	2 (4.8%)	4 (14.8%)
foveal tumor	26 (61.9%)	17 (63.0%)
Retinoblastoma seeds		
not seeds	17 (40.5%)	7 (25.9%)
subretinal	16 (38.1%)	10 (37.0%)
vitreous	9 (21.4%)	10 (37.0%)

487 IIRC, international intraocular retinoblastoma classification.

	Accuracy	Sensitivity	Specificity	Positive	Negative	F1 score
	(95% CI)	(95% CI)	(95% CI)	predictive	predictive	(95% CI)
				value (95%	value (95%	
				CI)	CI)	
Normal-active	0.992	0.979	1.000	1.000	0.988	0.989
retinoblastoma	[0.977-1.000]	[0.927-1.000]	[1.000-1.000]	[1.000-1.000]	[0.961-1.000]	[0.932-1.000]
identification						
Stable-active	0.934	0.978	0.800	0.937	0.923	0.957
retinoblastoma	[0.869-0.984]	[0.932-1.000]	[0.556-1.000]	[0.868-1.000]	[0.727-1.000]	[0.930-1.000]
identification						

489 Table 2. Performance of DLA-RB in prospective validation dataset,

490

492 **Table 3**. Confusion matrix of DLA-RB in identifying active retinoblastoma among

493 treated patients.

		DLA-RB				
		stable	active	total		
Gold	stable	12	3	15		
	active	1	45	46		
standard	total	13	48	61		

494

	Costs per person, \$	QALYs per person	Incremental costs per person, \$	Incremental QALYs per person	ICURs, \$
Diagnosis of RB					
DLA-RB-based diagnosis mode	3519	2.87240			
Traditional ophthalmologic	4882	2.87769	1363	0.00529	257645
centers-based diagnosis mode					
dentification of active lesion in treated					
retinoblastoma patients					
DLA-RB-based diagnosis mode	6981	5.46345			
Traditional ophthalmologic	7614	5.46436	633	0.00091	694323
centers-based diagnosis mode					

496 **Table 4.** Base-case cost-utility results.

497 DLA-RB, Deep Learning Assistant for retinoblastoma; ICUR, incremental cost-utility ratio; QALY,

498 quality-adjusted life-year.

499 Costs are given in US dollars. Negative ICURs are regarded as dominating.



Deep Learning Assistant for Retinoblastoma Monitoring (DLA-RB) System



